Clinical application of centrifugal‐membrane hybrid plasmapheresis in the treatment of hyperlipidemia.

Objective Methods Results Conclusion This study aimed to clarify the clinical application of centrifugal‐membrane hybrid plasmapheresis (CMHP) in the treatment of hyperlipidemia.A retrospective study was conducted on 48 patients who were diagnosed with hyperlipidemia and had received CMHP treatment. Serum total cholesterol (TC), triglycerides (TG), high‐density lipoprotein cholesterol (HDL‐C), and low‐density lipoprotein cholesterol (LDL‐C) were monitored, and adverse reactions to the treatment were observed.Forty‐eight patients with hyperlipidemia received CMHP over 59 sessions. The average age of the 48 patients with hyperlipidemia, including 32 males (66.67%) and 16 females (33.33%), was 44.23 ± 12.02 years. Twenty‐nine outpatients (60.42%) and 19 inpatients (39.58%) were included. Hypertriglyceridemia was diagnosed in 16 cases (33.33%), mixed hyperlipidemia in 31 cases (64.58%), and hypercholesterolemia in one case (2.08%). The pretreatment blood lipid concentrations were significantly different after the 59 CMHP treatments (p < .001). The concentrations of TC, TG, HDL‐C, and LDL‐C decreased significantly after the treatment, and the median ratios of reduction were 67.06% (range: 58.97%–71.87%), 63.33% (range: 55.20%–74.86%), 45.87% (range: 35.86%–52.95%), and 66.09% (range: 44.37%–73.94%), respectively. Three adverse reactions (5.08%) were recorded. No differences were detected in therapeutic parameters, effects, or adverse reactions between the two blood cell separators, there was no difference in Lipoprotein apheresis efficacy.This preliminary study demonstrated the clinical application of CMHP in patients in the treatment of hyperlipidemia. However, further studies are needed applying CMHP with hyperlipidemia. [ABSTRACT FROM AUTHOR]